Low-Dose Tirzepatide Produces Meaningful Weight Loss in Just 12 Weeks in Real-World Use | Research

The takeaway

A real-world study of 115 adults with obesity (no diabetes) found significant weight loss with low-dose tirzepatide (2.5-5mg) in just 12 weeks.

Significant weight loss at 12 weeks
Low-dose tirzepatide (2.5-5mg) effective in real-world obesity treatment

What the researchers found

Low-dose tirzepatide (2.5-5mg) produced significant weight loss and metabolic improvements in 12 weeks in adults with obesity without diabetes.

Why it matters

Real-world evidence at lower doses and shorter durations helps set realistic expectations for patients starting tirzepatide and supports cost-effective prescribing.

How the study worked

Prospective multicenter observational study; 115 adults with obesity without diabetes; tirzepatide 2.5mg (4 weeks) then 5mg (8 weeks); anthropometric and biochemical assessments.

What this study cannot tell us

No control group; observational design; 12 weeks is short for assessing sustainable weight loss; small sample.

How to read the evidence

Prospective observational study — provides real-world effectiveness data but lacks randomization and placebo control.

When this study was published

Published 2026 in International Journal of Obesity.

The bigger picture

Demonstrating effectiveness at lower doses may help address supply constraints and cost barriers that limit access to tirzepatide for many patients.

Questions still open

Is weight loss sustained or does it plateau at these lower doses?
How do these real-world results compare to clinical trial data at equivalent doses?

Common questions

Does tirzepatide work at low doses?

Yes — this study found that even the lowest doses (2.5mg and 5mg) produced significant weight loss within 12 weeks in people with obesity who don't have diabetes.

How quickly does tirzepatide start working?

This study showed meaningful weight loss and metabolic improvements within just 12 weeks at starting doses, suggesting benefits begin early in treatment.

Read the original research

A real-world study of tirzepatide for weight loss in adults without diabetes mellitus.

International journal of obesity (2005), 50(3), 684-688

View on PubMed ↗Publisher’s paper ↗

Citation

Angelopoulos, Nikolaos; Androulakis, Ioannis; Rizoulis, Andreas; Boniakos, Anastasios; Fousteris, Evangelos; Mentzelopoulou, Voula; Petkova, Valentina; Paparodis, Rodis; Zianni, Dimitra; Florakis, Dimos; Korakovouni, Areti; Mouslech, Zadalla; Livadas, Sarantis; Tzoulis, Ploutarchos. (2026). A real-world study of tirzepatide for weight loss in adults without diabetes mellitus.. International journal of obesity (2005), 50(3), 684-688. https://doi.org/10.1038/s41366-025-01986-0